Value & Access Experts Explain Price for Progress at EuroMeeting 2017

Through breakthrough therapy designations, adaptive designs and other innovations, the global regulatory environment is evolving to deliver therapeutic products to patients more quickly, although sometimes with less clinical data. Claes Buxfeldt, Global Price and Reimbursement Director at AstraZeneca in Sweden, and Ana Palma, Lead, Global HTA and Patient Access at Sobi in Belgium, explain how payer and health technology assessment processes are evolving to assess the value of these products, and preview Theme 8: HTA, Value & Access, which they will co-chair at DIA’s EuroMeeting 2017 in Glasgow. “There’s no point in reaching an internal agreement within a company and then eventually an agreement with a regulatory agency if down the road we will hit a wall with the reimbursement agency,” Ana explains. Register for our DIA EuroMeeting 2017 in Glasgow!